MAPT and Alzheimer disease: The cellular levels of p-tau were measured after treatment with the Ramalin derivatives (20 μM), and it was found that among the derivatives, RA-Sali exhibited the most significant inhibitory activity with an inhibition level of ~40%, further confirming the potential of these derivatives for use as multi-target therapeutic agents in AD treatment.